Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

Magnetic resonance imaging (MRI) holds great potential to spare men with suspected prostate cancer a painful biopsy. In our ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer ...

A “HOLY grail” blood test can pick up cancer cases with 84 per cent accuracy – even among patients who have been falsely ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...